BioPharmSignal logoBioPharmSignal

Biotech News

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Medicenna Therapeutics Corp. (MDNA)Medicenna Therapeutics Corp.Financing

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting

Related news

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ERASErasca2026-07-13 20:19 EST

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

LEGNLegend Biotech Corporation2026-06-18 01:21 EST

Legend Biotech Corporation Announces Pricing of Public Offering

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

MDNAMedicenna Therapeutics Corp.2026-06-11 11:00 EST

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

MDNAMedicenna Therapeutics Corp.2026-06-03 11:00 EST

Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

View all latest news

Medicenna Therapeutics Corp.

IL-2 Superkine Platform Medicenna Therapeutics develops engineered cytokines and fusion proteins intended to improve antitumor immune activity. Its Superkine platform modifies cytokine receptor selectivity, potency and pharmacology. MDNA11 MDNA11 is a long-acting beta-only IL-2 agonist in the Phase 1/2 ABILITY-1 study. It is being...

Recent company news

MDNAMedicenna Therapeutics Corp.2026-06-26 12:45 EST

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

MDNAMedicenna Therapeutics Corp.2026-06-11 11:00 EST

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

MDNAMedicenna Therapeutics Corp.2026-06-03 11:00 EST

Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

MDNAMedicenna Therapeutics Corp.2026-05-28 13:10 EST

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

MDNAMedicenna Therapeutics Corp.2026-05-22 11:00 EST

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States